These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

543 related items for PubMed ID: 11458049

  • 21. [Comparative study of BTA stat test, NMP-22, and cytology in the diagnosis of bladder cancer].
    Gutiérrez Baños JL, Rebollo Rodrigo MH, Antolín Juarez F, Martín García B, Hernández Rodríguez R, Portillo Martín JA, Correas Gómez MA, del Valle Schaan JI, Roca Edreira A, de Diego Rodríguez E, Radó Velázquez MA.
    Arch Esp Urol; 2000; 53(1):21-7. PubMed ID: 10730421
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Usefulness of urinary NMP22 to detect tumor recurrence of superficial bladder cancer after transurethral resection.
    Miyanaga N, Akaza H, Tsukamoto S, Shimazui T, Ohtani M, Ishikawa S, Noguchi R, Manabe F, Nishijima Y, Kikuchi K, Sato K, Hayashi H, Kondo F, Shiraiwa H, Aoyama O.
    Int J Clin Oncol; 2003 Dec; 8(6):369-73. PubMed ID: 14663639
    [Abstract] [Full Text] [Related]

  • 25. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer.
    Zippe C, Pandrangi L, Potts JM, Kursh E, Novick A, Agarwal A.
    Anticancer Res; 1999 Dec; 19(4A):2621-3. PubMed ID: 10470205
    [Abstract] [Full Text] [Related]

  • 26. Urinary level of nuclear matrix protein 22 in the diagnosis of bladder cancer: experience with 130 patients with biopsy confirmed tumor.
    Casella R, Huber P, Blöchlinger A, Stoffel F, Dalquen P, Gasser TC, Lehmann K.
    J Urol; 2000 Dec; 164(6):1926-8. PubMed ID: 11061883
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma.
    Babjuk M, Soukup V, Pesl M, Kostírová M, Drncová E, Smolová H, Szakacsová M, Getzenberg R, Pavlík I, Dvorácek J.
    Urology; 2008 Apr; 71(4):718-22. PubMed ID: 18387400
    [Abstract] [Full Text] [Related]

  • 30. [Usefulness of BTA Stat test (Bard) in the diagnosis of bladder cancer. Preliminary results and comparison with cytology and cystoscopy].
    Gutiérrez Baños JL, Martín García B, Hernández Rodríguez R, Portillo Martín JA, Correas Gómez MA, del Valle Schaan JI, Roca Edreira A, Villanueva Peña A, Gutíerrez García R, De Diego Rodríguez E, Rado Velázquez MA.
    Arch Esp Urol; 1998 Oct; 51(8):778-82. PubMed ID: 9859583
    [Abstract] [Full Text] [Related]

  • 31. Screening and monitoring for bladder cancer: refining the use of NMP22.
    Ponsky LE, Sharma S, Pandrangi L, Kedia S, Nelson D, Agarwal A, Zippe CD.
    J Urol; 2001 Jul; 166(1):75-8. PubMed ID: 11435827
    [Abstract] [Full Text] [Related]

  • 32. [Quantification of bladder tumor antigen (BTA trak) and its correlation with bladder cancer grade and stage].
    Rodríguez Martínez JJ, Escaf Barmadah S, Allende MT, Raigoso P, Martín Benito JL, Pérez García FJ, Fernández Gómez JM.
    Arch Esp Urol; 2000 Jul; 53(1):1-6. PubMed ID: 10730418
    [Abstract] [Full Text] [Related]

  • 33. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder.
    Jamshidian H, Kor K, Djalali M.
    Urol J; 2008 Jul; 5(4):243-7. PubMed ID: 19101898
    [Abstract] [Full Text] [Related]

  • 34. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM, García Rodríguez J, Escaf Barmadah S, Raigoso P, Rodríguez Martínez JJ, Allende MT, Casasola Chamorro J, Rodríguez Faba O, Martín Benito JL, Regadera Sejas FJ.
    Arch Esp Urol; 2002 Jul; 55(1):41-9. PubMed ID: 11957750
    [Abstract] [Full Text] [Related]

  • 35. [Urinary tumor marker for urothelial cancer].
    Ohtani M, Iwasaki A, Shiraiwa H.
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1933-7. PubMed ID: 11729491
    [Abstract] [Full Text] [Related]

  • 36. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group].
    Akaza H, Miyanaga N, Tsukamoto T, Ishikawa S, Noguchi R, Ohtani M, Kawabe K, Kubota Y, Fujita K, Obata K, Hirao Y, Kotake T, Ohmori H, Kumazawa J, Koiso K.
    Gan To Kagaku Ryoho; 1997 May; 24(7):837-42. PubMed ID: 9170522
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [Clinical evaluation of urinary basic fetoprotein and the BTA test for detection of bladder cancer].
    Imamura M, Inoue K, Megumi Y, Nishimura M, Ohmori K, Nishimura K.
    Hinyokika Kiyo; 2000 Oct; 46(10):705-9. PubMed ID: 11215195
    [Abstract] [Full Text] [Related]

  • 39. [Screening methods in the detection of bladder cancer: comparison of nuclear matrix protein-22, bladder tumor antigen and cytological examinations].
    Fukui Y, Samma S, Fujimoto K, Akiyama T, Yamaguchi A, Hirayama A.
    Hinyokika Kiyo; 2001 May; 47(5):311-4. PubMed ID: 11433750
    [Abstract] [Full Text] [Related]

  • 40. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
    Shariat SF, Herman MP, Casella R, Lotan Y, Karam JA, Stenman UH.
    Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.